Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Treatment with Rituximab in Rheumatoid Pneumoconiosis: A Case Report

Author(s): Makhlouf Yasmine*, Maatallah Kaouther, Kaffel Dhia, Ferjani Hanene, Triki Wafa, Ben Nessib Dorra and Hamdi Wafa

Volume 18, Issue 3, 2023

Published on: 10 June, 2022

Page: [383 - 385] Pages: 3

DOI: 10.2174/1574886317666220428132311

Price: $65

conference banner
Abstract

Background: Caplan's syndrome, also known as rheumatoid pneumoconiosis (RP), is a rare disease associating pneumoconiosis with rheumatoid arthritis (RA). This is one of the rare cases evaluating the effect of Rituximab, which was used initially for the treatment of RA, on pneumoconiosis

Case Presentation: In this case report, we described a 21-year long-standing history of pneumoconiosis and its association with RA. A 67-year-old man diagnosed with pneumoconiosis presented with morning stiffness and symmetrical polyarthritis. Laboratory investigations showed high titers of rheumatoid factor (RF) and anti-citrullinated protein antibodies. The diagnosis of RA was established and the patient was put on leflunomide. Then, he was treated with Rituximab, as he did not respond to leflunomide. The patient showed marked improvement as pain and swelling decreased. More importantly, Caplan’s nodules stabilized on chest-computed tomography.

Conclusion: The use of rituximab in pneumoconiosis does not alter the evolution of the pulmonary nodules. More trials are needed to establish a treatment consensus for RP.

Keywords: Caplan syndrome, rheumatoid arthritis, rituximab, pneumoconiosis, AID, silicosis.

« Previous Next »
[1]
Caplan A. Certain unusual radiological appearances in the chest of coal-miners suffering from rheumatoid arthritis. Thorax 1953; 8(1): 29-37.
[2]
Caplan A, Payne RB, Withey JL. A broader concept of Caplan’s syndrome related to rheumatoid factors. Thorax 1962; 17(3): 205-12.
[3]
Schreiber J, Koschel D, Kekow J, Waldburg N, Goette A, Merget R. Rheumatoid pneumoconiosis (Caplan’s syndrome). Eur J Intern Med 2010; 21(3): 168-72.
[http://dx.doi.org/10.1016/j.ejim.2010.02.004] [PMID: 20493416]
[4]
Peukert W. Contribution to Caplan’s syndrome. Dtsch Gesundheitsw 1967; 22(38): 1803-7.
[PMID: 5600830]
[5]
Tichy H, Böhme A. On the serology of silicosis with and without polyarthritis. Z Rheumaforsch 1963; 22: 89-99.
[PMID: 13984989]
[6]
Brueckner L, Rosmanith J. Caplan’s syndrome in miners in the Ostrava-Karvina coal mining district. Radiol Diagn (Berl) 1962; 3: 1-12.
[PMID: 13873872]
[7]
Klockars M, Koskela RS, Järvinen E, Kolari PJ, Rossi A. Silica exposure and rheumatoid arthritis: A follow up study of granite workers 1940-81. Br Med J (Clin Res Ed) 1987; 294(6578): 997-1000.
[http://dx.doi.org/10.1136/bmj.294.6578.997] [PMID: 2823951]
[8]
Parkes W. Pneumoconiosis associated with coal and other carbonaceous materialsOccupational lung disorders. (3rd ed.). Oxford: ButterworthHeinemann 1994; pp. 340-410.
[9]
Hunninghake GW, Fauci AS. Pulmonary involvement in the collagen vascular diseases. Am Rev Respir Dis 1979; 119(3): 471-503.
[PMID: 36018]
[10]
Nakamura T, Shiraishi N, Morikami Y, Fujii H, Yoshinaga T. Amyloid A amyloidosis in a patient with Caplan’s syndrome, with special reference to genetic predisposition. Mod Rheumatol Case Rep 2020; 4(2): 212-7.
[http://dx.doi.org/10.1080/24725625.2020.1749361] [PMID: 33087017]
[11]
Darke C, Wagner MMF, Nuki G, Dyer PA. HLA-A, B and DR antigens and properdin factor B allotypes in Caplan’s syndrome. Br J Dis Chest 1983; 77(3): 235-42.
[http://dx.doi.org/10.1016/0007-0971(83)90048-7] [PMID: 6577907]
[12]
Burke GW, Carrington CB, Grinnan R. Pulmonary nodules and rheumatoid factor in the absence of arthritis. Chest 1977; 72(4): 538-40.
[http://dx.doi.org/10.1378/chest.72.4.538] [PMID: 908228]
[13]
Scadding JG. The lungs in rheumatoid arthritis. Proc R Soc Med 1969; 62(3): 227-38.
[http://dx.doi.org/10.1177/003591576906200306] [PMID: 5768324]
[14]
Kuijpers TW, Bende RJ, Baars PA, et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest 2010; 120(1): 214-222Md.
[15]
Md Yusof MY, Kabia A, Darby M, et al. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years’ experience at a single centre. Rheumatology (Oxford) 2017; 56(8): 1348-57.
[http://dx.doi.org/10.1093/rheumatology/kex072] [PMID: 28444364]
[16]
Berghen N, Vulsteke JB, Westhovens R, Lenaerts J, De Langhe E. Rituximab in systemic autoimmune rheumatic diseases: Indications and practical use. Acta Clin Belg 2019; 74(4): 272-9.
[http://dx.doi.org/10.1080/17843286.2018.1521904] [PMID: 30253707]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy